Facebook
Twitter
LinkedIn
Forward36th Annual Pittsburgh Schizophrenia Conference
The Pittsburgh Schizophrenia Conference is an annual meeting at which the advances in schizophrenia research are reviewed by experts in the field. This year’s meeting will cover early identification and management of first episode psychoses based on knowledge obtained and disseminated from a NIMH funded trial. Attendees will learn and review immune-inflammatory mechanisms that play a role in subgroups of persons with schizophrenia, especially gluten sensitivity and ongoing work to remediate this sensitivity. Participants will hear about transcranial magnetic stimulation (TMS) and its potential use in schizophrenia. From a case example, attendees will learn about clarifying diagnosis and optimizing medications in persons with mental illness in a residential facility. Finally, attendees will hear from people with serious mental illness who will share their stories of working as Peer Specialists and of using music to help support their recovery.
Target Audience
The conference is designed to disseminate the latest clinical and research findings to a wide audience: psychiatrists and other mental health clinicians, including nurses, social workers, psychologists, service coordinators, researchers, patients and their relatives, mental health policy administrators and others who intend to keep current regarding treatment research in schizophrenia.
Learning Objectives
At the completion of the program, participants should be able to:
1. Recognize the essential elements of coordinated specialty care early in the course of schizophrenia.
2. Recognize the concept of the duration of untreated psychoses and steps taken to reduce the duration.
3. Discuss ongoing research to characterize a subgroup of schizophrenia patients with immune response and inflammation to gluten.
4. Identify potential pathophysiologic mechanisms related to an immune response to gluten.
5. Explain ongoing work for personalizing treatment in this subgroup of schizophrenia with potential gluten sensitivity.
6. Recognize the basic mechanisms of non-invasive brain activity modulation with TMS.
7. Review the safety profile of TMS treatments.
8. Review studies investigating the use of TMS in patients with schizophrenia and psychotic disorders.
9. Discuss if a step down longer stay residential placement provides value for clarifying the diagnosis and revisit the treatment approach to persons with serious mental illness.
Additional Information
| Attachment | Size |
|---|---|
 CME Handout (002) APPROVED.pdf | 247.17 KB |
7:30 am Registration and Continental Breakfast
8:30 am Introduction and Background K.N. Roy Chengappa, MD
8:45-10:15 am The Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Award
8:45 to 9:00 am Review of Dr. Kane’s work
Shaun M. Eack, PhD
Presentation of plaque to John M. Kane, MD
Susan Hogarty, RN, MSN
9:00-10:15 am Gerard E. Hogarty Excellence in Schizophrenia Research
Memorial Lecture
Lessons Learned from RAISE-ETP: Where Do We Go from Here?
John M. Kane, MD
9:00 to 10:00 Presentation
10:00 to 10:15 Q&A session
10:15-10:30 am Break
10:30-11:45 am Gluten and Schizophrenia: New Target and Precision Medicine?
Deanna L. Kelly, Pharm.D., BCPP
10:30-11:30 Presentation
11:30-11:45 Q&A session
11:45-1:00 pm Lunch (on own)
1:00-2:15 pm Transcranial Magnetic Stimulation (TMS) in Schizophrenia and Psychosis – 2019 Update
Steven D. Forman MD, PhD
1:00-2:00 Presentation
2:00-2:15 Q&A session
2:15 – 3:30 pm Deprescription and Optimization of Medications
Vernon Nathaniel, MD
Susan Wolfe, MA LPC, Program Director CTT
Stacy Martin, LSW, Behavioral Health Counselor
2:15-3:15 Presentation
3:15-3:30 Q&A session
3:30 - 3:40 pm Break
3:40 – 4:40 pm Peer Specialists: Sharing and Working
Susan Brown Padilla, CPS, Senior Peer Specialist
Bernice Hayes, CPS, Senior Peer Specialist
Flavio Chamis, Music Director and peer musicians
4:40-4:50 Closing Remarks and Adjournment K.N. Roy Chengappa, MD
Course Director
K.N. Roy Chengappa, MD
Professor of Psychiatry
University of Pittsburgh School of Medicine
Chief, Comprehensive Recovery Services
UPMC Western Psychiatric Hospital
Pittsburgh, PA
Gerard E. Hogarty Excellence in Schizophrenia Research Memorial Award Winner
John M. Kane, MD
Senior Vice President for Behavioral Health Services
Northwell Health
New Hyde Park, NY
Professor and Chairman
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
The Zucker Hillside Hospital
Glen Oaks, NY
Faculty
Steven D. Forman MD, PhD
Staff Physician & Research Investigator
Program Chief, Transcranial Magnetic Stimulation Clinic
VA Pittsburgh Healthcare System
Assistant Professor of Psychiatry
University of Pittsburgh School of Medicine
Pittsburgh, PA
Bernice Hayes, CPS Senior Peer Specialist UPMC Western Psychiatric Hospital Pittsburgh, PA
Deanna L. Kelly, PharmD., BCPP Professor of Psychiatry Director, Treatment Research Program (TRP) Maryland Psychiatric Research Center (MPRC) University of Maryland School of Medicine
Shaun M. Eack, PhD David E. Epperson Professor of Social Work Professor of Psychiatry School of Social Work and Department of Psychiatry University of Pittsburgh UPMC Western Psychiatric Hospital Pittsburgh, PA
Susan Hogarty, RN, MSN Psychiatric Clinical Nurse Specialist Research Program Administrator ASCEND Program Comprehensive Recovery Services UPMC Western Psychiatric Hospital Pittsburgh, PA
Stacy Martin, LSW Behavioral Health Counselor UPMC Western Psychiatric Hospital Pittsburgh, PA
Vernon Ian Nathaniel, MD Assistant Professor of Psychiatry University of Pittsburgh School of Medicine Medical Director and Attending Psychiatrist Community Treatment Team-Transitional Age UPMC Western Psychiatric Hospital Pittsburgh, PA
Susan Brown Padilla, CPS Senior Peer Specialist UPMC Western Psychiatric Hospital Pittsburgh, PA
Susan Wolfe, MA, LPC Program Director Community Treatment Team (CTT) UPMC Western Psychiatric Hospital Pittsburgh, PA
Panel Moderator
Flavio Chamis
Composer, Conductor, Educator, Music Consultant and Producer
All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.
The following relevant financial relationships were disclosed:
Steven D. Forman, MD, PhD Stockholder: Neurocrine
John M. Kane, MD Grant/Research Support:
Otsuka, Lundbeck, Janssen
Consultant:
Forum, Allergan, Alkermes, Eli Lilly, Genentech, Lundbeck, Intracellular Therapies, Janssen, Johnson & Johnson, Neurocrine, Otsuka, Pierre Fabre, Merck, Reviva, Roche, Sunovion, Takeda, Teva
Stockholder: Vanguard Research Group, LB Pharmaceuticals
Other: Advisory Board: Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Takeda, Teva, Pierre Fabre
Deanna L. Kelly, PharmD, BCPP Consultant: Alkermes, HLS Therapeutics
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 6.50 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 6.50 Attendance